Home / Health / New Policy Eases Access to Popular Unapproved Peptides
New Policy Eases Access to Popular Unapproved Peptides
17 Nov
Summary
- Six peptides now easier to obtain through doctors and pharmacies.
- FDA has not approved them, but is easing enforcement actions.
- Policy aims to improve safety and reduce gray-market production.

A new interim policy from the Department of Health and Human Services (HHS) is making six popular peptides more accessible. These peptides, including BPC-157 and TB-500, can now be more readily obtained through physicians and licensed pharmacies, provided specific conditions are met. This policy, announced in late October 2026, does not constitute FDA approval for these compounds.
The HHS policy focuses on reducing enforcement actions against healthcare providers preparing these peptides. The agency's goal is to improve safety and curb the production of unverified peptides often sold online. Many Americans are already using these substances, often seeking them for tissue repair and injury recovery.
To access these peptides, a prescription from a physician is required. The policy supports traditional patient-specific compounding and emphasizes medical oversight, which users have indicated increases their trust. Public comments on the policy are due by November 13, 2026, which may influence longer-term FDA decisions.
Further reviews are planned for other peptides in early 2027. The HHS may revise or withdraw its current policy if safety or quality issues arise, meaning access could potentially change.